However, the impact of colchicine on the autophagy activity within cardiomyocytes remains inadequately elucidated. Recent studies have highlighted the beneficial effects of colchicine on patients with pericarditis, postprocedural atrial fibrillation, and coronary artery disease. It remains ambiguous how ...
“The magnitude of colchicine's benefits, 23% and 34% for first and total — including recurrent — primary endpoint CV events, on a background of excellent standard of care, is surprising,” Tardif said in an interview. “The excellent tolerability profile o...
He was started on aspirin and colchicine with marked improvement of his symptoms prior to discharge. Conclusions We present a case of perimyocarditis that was temporally related to COVID-19 mRNA vaccination in an young male with prior COVID-19 infection but otherwise healthy. Our case report ...
After careful consideration the patient elected to forego the 2nd dose of the vaccine. He was discharged with plans to complete a two week course of aspirin, three months of colchicine, and metoprolol. He was instructed to avoid alcohol intake and significant physical exertion for three to six ...
We retrospectively analyzed 9 patients (1994 to 2010) with refractory recurrent pericarditis, who received high-dose IvIg as a part of their medical treatment. Nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, or colchicine treatment was not discontinued during IvIg treatment. No patients had...
care unit, specific cardioprotective heart failure therapy was started and, due to the high possibility of requiring high doses of cytarabine in subsequent oncological management, therapy with Non-Steroidal Anti-inflammatory drugs and colchicine was given to reduce the risk of myopericarditis recurrence...
In recent years, COL has also been shown to have good therapeutic potential in cardiovascular diseases such as pericarditis, coronary artery disease, and acute myocardial infarction [2–4]. In June 2023, the US FDA approved 0.5 mg colchicine tablets, LODOCO® (manufactured in AGEPHA Pharma, ...